Renaissance Technologies's MDGL Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 83,862 shares of Madrigal Pharmaceuticals, Inc. (MDGL) worth $48.84 M, representing 0.08% of the portfolio. First purchased in 2016-Q3, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in MDGL, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 170,800 shares. Largest reduction occurred in Q2 2023, reducing 96,700 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Madrigal Pharmaceuticals (MDGL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Madrigal Pharmaceuticals (MDGL) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -36,820 | Reduce 30.51% | 83,862 | $582.34 |
| Q3 2025 | +109,846 | Add 1013.71% | 120,682 | $458.66 |
| Q2 2025 | -74,250 | Reduce 87.26% | 10,836 | $302.64 |
| Q1 2025 | -75,696 | Reduce 47.08% | 85,086 | $331.23 |
| Q4 2024 | +116,285 | Add 261.33% | 160,782 | $308.57 |
| Q3 2024 | +44,497 | New Buy | 44,497 | $212.22 |
| Q4 2023 | -68,082 | Sold Out | 0 | $0.00 |
| Q3 2023 | -10,600 | Reduce 13.47% | 68,082 | $146.04 |
| Q2 2023 | -96,700 | Reduce 55.14% | 78,682 | $0.23 |
| Q1 2023 | +170,800 | Add 3727.63% | 175,382 | $0.24 |
| Q4 2022 | +4,582 | New Buy | 4,582 | $0.29 |
| Q2 2022 | -4,800 | Sold Out | 0 | $0.00 |
| Q1 2022 | +2,400 | Add 100.00% | 4,800 | $98.12 |
| Q4 2021 | -14,711 | Reduce 85.97% | 2,400 | $84.58 |
| Q3 2021 | -35,871 | Reduce 67.70% | 17,111 | $79.77 |
| Q2 2021 | +18,700 | Add 54.55% | 52,982 | $97.41 |
| Q1 2021 | +249 | Add 0.73% | 34,282 | $116.97 |
| Q4 2020 | +12,251 | Add 56.24% | 34,033 | $111.16 |
| Q3 2020 | -50,600 | Reduce 69.91% | 21,782 | $118.72 |
| Q2 2020 | +45,900 | Add 173.33% | 72,382 | $113.25 |
| Q1 2020 | +26,482 | New Buy | 26,482 | $66.76 |
| Q1 2018 | -87,587 | Sold Out | 0 | $0.00 |
| Q4 2017 | -39,700 | Reduce 31.19% | 87,587 | $91.79 |
| Q3 2017 | +51,900 | Add 68.84% | 127,287 | $44.98 |
| Q2 2017 | +17,512 | Add 30.26% | 75,387 | $16.26 |
| Q1 2017 | +400 | Add 0.70% | 57,875 | $15.40 |
| Q4 2016 | +4,488 | Add 8.47% | 57,475 | $14.89 |
| Q3 2016 | +52,987 | New Buy | 52,987 | $12.68 |
Renaissance Technologies's Madrigal Pharmaceuticals Investment FAQs
Renaissance Technologies first purchased Madrigal Pharmaceuticals, Inc. (MDGL) in Q3 2016, acquiring 52,987 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Madrigal Pharmaceuticals, Inc. (MDGL) for 28 quarters since Q3 2016.
Renaissance Technologies's largest addition to Madrigal Pharmaceuticals, Inc. (MDGL) was in Q1 2023, adding 175,382 shares worth $42,488.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 83,862 shares of Madrigal Pharmaceuticals, Inc. (MDGL), valued at approximately $48.84 M.
As of the Q4 2025 filing, Madrigal Pharmaceuticals, Inc. (MDGL) represents approximately 0.08% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Madrigal Pharmaceuticals, Inc. (MDGL) was 175,382 shares, as reported at the end of Q1 2023.